Understanding the Groundbreaking MND Insight Research
The release of the first findings from the MND Insight Research study marks a pivotal moment in New Zealand's efforts to improve care for those living with motor neurone disease (MND). Published on January 30, 2026, in the New Zealand Medical Journal, this nationwide survey reveals stark realities about treatment access, particularly the low uptake of riluzole—the only publicly funded medication proven to extend survival in amyotrophic lateral sclerosis (ALS), the most common form of MND. Led by a collaborative team of clinicians, pharmacists, and academics from leading New Zealand universities, the study draws from responses by 115 people with ALS, highlighting systemic gaps that leave many Kiwis without this vital therapy.
Motor Neurone Disease New Zealand (MND NZ), the charity spearheading the research, invited participants via email and the national MND Registry. The data underscores not just usage rates but also the human stories behind decisions to start, stop, or never begin treatment. As Dr. Natalie Gauld, lead investigator and a person living with MND herself, notes, "It has been concerning to see our riluzole uptake is so low when compared internationally." This work, rooted in patient voices, calls for immediate action to bridge these gaps.
Demystifying Motor Neurone Disease in Aotearoa
Motor neurone disease, known as MND or amyotrophic lateral sclerosis (ALS) in its primary variant, is a progressive neurodegenerative condition affecting the nerve cells responsible for controlling voluntary muscles. It leads to muscle weakness, paralysis, difficulties with speech, swallowing, and breathing, ultimately proving fatal. In New Zealand, around 400 people live with MND at any time, with two new diagnoses each week—translating to approximately 144 cases annually, or a rate of about three per 100,000 people, among the highest globally.
Unlike many diseases, MND has no cure, and symptoms worsen relentlessly. Limb-onset cases (about 73%) start in arms or legs, while bulbar-onset (27%) begin with speech or swallowing issues, complicating treatment from the outset. Average survival post-diagnosis is 2-3 years, with half passing within 30 months of symptom onset. Cultural context in Aotearoa adds layers: Māori, comprising 6% of study respondents, face potential inequities in access, echoing broader health disparities.
University researchers, such as those from the University of Auckland and University of Otago, play a crucial role in unraveling MND's epidemiology. Studies confirm New Zealand's elevated incidence, prompting investigations into genetic, environmental, or lifestyle factors. For those pursuing careers in neurology or epidemiology, opportunities abound in research jobs at these institutions, contributing to global understanding.
Riluzole: The Science Behind the Only Funded Lifeline
Riluzole (brand name Rilutek), a glutamate release inhibitor, is the sole disease-modifying drug funded by PHARMAC for ALS in New Zealand since 2013. Administered as 50mg tablets twice daily on an empty stomach, it modestly slows neurodegeneration by reducing excessive glutamate, which overexcites motor neurons. Original pivotal trials in the 1990s showed a median survival extension of 2-3 months compared to placebo.
However, real-world evidence paints a more promising picture. Population studies report gains of 6-19 months, with recent analyses suggesting 7-11 months on average—benefits amplified when started early. For instance, a comprehensive review of observational data found significant survival differences between riluzole users and non-users. Despite this, discontinuation affects 20% of starters due to side effects like nausea, fatigue, elevated liver enzymes, or rash, though most tolerate it well with monitoring.
In practice, prescribers must navigate special authority criteria, but most ALS patients qualify. Yet, as the study reveals, practical hurdles persist. Tablets prove challenging for those with dysphagia or feeding tubes—crushing risks clogs, and no liquid formulation exists locally, unlike overseas. Pharmacy experts from the University of Auckland's School of Pharmacy, like co-author Natalie Gauld, advocate for formulation innovations.
Key Statistics from the MND Insight Research
Of 115 ALS respondents (64% male, median age 67, 88% NZ European), 55 (48%) currently take riluzole, 14 (12%) discontinued, and 42 (36%) never started—a stark 52% non-current use rate. Adherence among users is high: 81% miss no doses weekly. Factors linked to lower uptake include bulbar onset (p<0.05), private diagnoses, and pre-2013 cases.
| Category | Number (%) |
|---|---|
| Current users | 55 (48%) |
| Previous users | 14 (12%) |
| Never used | 42 (36%) |
| Bulbar onset users | Lower than limb (p<0.05) |
| Discontinuation rate | 20% |
Never-users cited: not offered (primary), doubts on efficacy ("3 months not worth it"), side effects. Discontinuers: side effects (rash, nausea, etc.). These figures contrast sharply with international benchmarks.
Barriers to Riluzole Adoption Exposed
The study illuminates multifaceted barriers. Many simply weren't offered riluzole—neurologists occasionally deem it unworthy due to outdated trial data emphasizing modest gains. Patient misconceptions abound: fears of caffeine interactions (debunked), quality-of-life trade-offs, or preference for "natural" alternatives. Bulbar patients face swallowing woes early, deterring prescription.
- Not prescribed or offered by clinician
- Perceived minimal benefit vs. side effects
- Swallowing difficulties (no liquid option)
- Lack of up-to-date information
- Private sector lower uptake
Family whānau reports echo challenges with tube feeding. MND NZ and researchers urge updating datasheets, websites, and clinician education. For Māori patients, culturally responsive info is key, as highlighted by University of Auckland's Dr. Joanna Hikaka from Te Kupenga Hauora Māori.
Photo by Andrew Hughes on Unsplash
International Comparisons Highlight New Zealand's Lag
New Zealand's 48% uptake pales against peers: 83% in four European ALS centers, 91% in US/Northern Ireland, 76% Australia, 61-85% Italy. Even Scotland's 40% current use exceeds in initiation. Higher discontinuation (20% vs. 14-17%) compounds the issue. These disparities signal opportunities: NZ's collaborative model, blending patient advocacy with academic rigor, can drive change.
Dr. James Cleland, neurologist and Honorary Senior Lecturer at the University of Auckland, emphasizes, "New Zealand can play a meaningful role in advancing MND research... clinical practice must adapt as evidence changes."
University Researchers Driving MND Innovation
This study exemplifies higher education's impact on public health. Co-authors hail from the University of Auckland (School of Pharmacy, General Practice, Te Kupenga Hauora Māori) and University of Otago (Dunedin School of Medicine, Dept. of Medicine). Natalie Gauld (Honorary Senior Clinical Lecturer), James Cleland (Honorary Senior Lecturer), Joanna Hikaka (Senior Lecturer), Sarah Buchanan (Senior Lecturer), Chris Frampton (Professor), and Stephen Buetow (Associate Professor) blend clinical and academic expertise.
Such interdisciplinary teams fuel discoveries, from registries to trials. Aspiring researchers can explore research assistant jobs or postdoc positions in neurology and pharmacy, advancing MND care. The MND NZ Registry, supported by unis, now aims for 300 enrollees by 2026.
The Push for Liquid Riluzole Funding
A core recommendation: fund liquid riluzole. Tablets fail late-stage patients with dysphagia or percutaneous endoscopic gastrostomy (PEG) tubes—crushing invites blockages and uneven dosing. Overseas liquids simplify administration via tubes or spoon, boosting uptake. MND NZ, with Gauld and CEO Mark Leggett, has petitioned PHARMAC and Medsafe.
This aligns with global trends; NZ lags despite evidence. Implementation could mirror funding expansions, enhancing equity—especially for bulbar cases (lower uptake) and Māori communities.
Implications for MND Care and Policy in New Zealand
Beyond riluzole, findings spotlight care inequities: public vs. private diagnoses, onset type. Updating clinician knowledge—emphasizing real-world 7-11 month gains—could transform prescriptions. Conferences like the neurological association event (Nov 2025) disseminated results to specialists.
Stakeholder views converge: patients seek info, clinicians evidence, policymakers efficiency. Broader MND strategy includes key workers reducing admissions, assistive tech. For higher ed, this underscores pharmacy and medicine's translational role. Explore academic career advice for entering this field.
Future Outlook: Research, Trials, and Hope
MND Insight Research continues, with planned papers on experiences, needs. NZ's registry facilitates trials; past efforts tested edaravone precursors. Emerging therapies like tofersen (genetic ALS) loom, but riluzole remains foundational. Universities drive this: Auckland/Otago host labs probing genetics, biomarkers.
- Ongoing MND Registry expansion
- Calls for updated guidelines
- Potential liquid funding 2026
- Interdisciplinary uni collaborations
Optimism tempers reality: every month gained matters. Check higher ed jobs in research for impact.
Photo by Partha Narasimhan on Unsplash
Actionable Insights for Patients, Families, and Clinicians
For newly diagnosed: Discuss riluzole early—monitor liver function quarterly, manage nausea with timing. Whānau: Advocate for info. Clinicians: Share real-world data, consider bulbar needs. Explore MND NZ resources. Professionals: Engage via NZ academic opportunities.
In summary, this university-led research catalyzes change, positioning Aotearoa as MND research leader. Visit Rate My Professor for uni insights, higher ed jobs, career advice, or university jobs to join the fight.